Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Eledon Pharmaceuticals Inc
NASDAQ ELDN
Data sourced from
and
and
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -88.55%
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) is -88.55% for the Trailing 12 Months (TTM) ending March 31, 2024, a 47.99% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
-
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -1.80, a -170.26% change year over year.
-
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.66, a 77.22% change year over year.
-
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -2.92, a 38.02% change year over year.
-
Eledon Pharmaceuticals Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -4.71, a -69.32% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ELDN
| CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
| IPO Date | Sept. 17, 2014 |
| Location | United States |
| Headquarters | 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Acumen Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email